American Diabetes Association - 67th Scientific Sessions: pros and cons of GLP-1 agonists and DPP-IV inhibitors.
Toft
Anders Dyhr
AD
Novo Nordisk A/S, Hummeltoftevej 49, DK-2830, Virum, Denmark. adto@novonordisk.com
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*